Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Colorectal Cancer · Metastatic Colorectal Adenocarcinoma · Unresectable Colorectal Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Peking University Shenzhen Hospital, Shenzhen, Guangdong, China
Contact: Study coordinator (Zhen J Peng, Phd) · Zhen-Peng@beijing-biotech.com · +86 13076790039

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC

Rectal Cancer · Radiotherapy

Abroad (travel likely)RecruitingPHASE2

Nanjing, China

Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases

Colorectal Cancer Metastatic · Liver Metastases · Colorectal Cancer

Abroad (travel likely)RecruitingPHASE2

New York, United States

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

Cancer · Breast Cancer · Non-Small Cell Lung Cancer (NSCLC)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Beijing, China

Interest of PET-MRI in the Evaluation of the Response After Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma

Rectal Cancer

Abroad (travel likely)Recruiting

Strasbourg, France